Saturday 17 October 2026
Export VTGN’s income statement to Excel — free account
VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
0.20
0.01
−4.76%
Follow VTGN
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Altman Z-Score |
(16.79) | (4.64) | 2.76 | (28.58) | 8.77 | 4.47 | — | — | — | (58.82) |
P/S ratio |
17.10 | 158.83 | 98.23 | 0.00 | 221.39 | 78.34 | — | — | — | 7.67 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(34.55) | (9.52) | 7.76 | (63.98) | (3.41) | 4.25 | — | — | — | (139.49) |
P/Operating CF |
(1.34) | (7.67) | (14.96) | (3.35) | (15.75) | (34.70) | — | — | — | (11.40) |
P/B ratio |
0.61 | 1.10 | 0.91 | 2.07 | 3.79 | 1.99 | — | — | — | 24.10 |
Price to Tangible BV |
0.61 | 1.10 | 0.91 | 2.07 | 3.79 | 1.99 | — | — | — | 24.10 |
EV/Sales |
(12.13) | 10.33 | (5.96) | (73.68) | 169.78 | 39.25 | — | — | — | 10.48 |
EV/EBITDA |
0.21 | 0.00 | 0.19 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
EV/Operating CF |
0.23 | (0.12) | 0.25 | (0.34) | (4.16) | (7.61) | — | — | — | (2.77) |
EV/FCF |
0.23 | (0.12) | 0.25 | (0.33) | (4.14) | (7.43) | — | — | — | (2.69) |
Quick Ratio |
3.55 | 6.38 | 23.26 | 3.64 | 11.82 | 24.61 | 0.49 | 4.78 | 7.12 | 2.14 |
Current Ratio |
3.67 | 6.51 | 23.55 | 3.83 | 12.32 | 24.86 | 0.57 | 4.87 | 7.56 | 2.47 |
Net Debt/EBITDA |
0.63 | 1.43 | 3.62 | 0.28 | 1.43 | 5.79 | 0.07 | 0.54 | 0.73 | 0.29 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.05% | 0.04% | 0.08% | 0.32% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Asset Turnover |
0.02 | 0.00 | 0.01 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.53 |
Operating CF/Net income |
0.95 | 0.82 | 0.88 | 0.84 | 0.93 | 0.29 | 0.72 | 0.56 | 0.58 | 0.62 |
Capex/Depreciation |
0.44 | 0.80 | (0.48) | (1.63) | (1.31) | (2.34) | 0.00 | (0.82) | (0.02) | (1.73) |
Interest Coverage |
— | — | — | (1,204.63) | (2,400.95) | (1,228.34) | 691.08 | (3,069.54) | (1,595.46) | (2,227.93) |
| (131.59%) | (55.68%) | (46.47%) | (154.30%) | (62.17%) | (98.14%) | (3,294.60%) | (367.99%) | (414.00%) | 980.11% | |
| (104.86%) | (49.44%) | (40.57%) | (123.78%) | (53.25%) | (74.21%) | (222.78%) | (203.48%) | (207.80%) | (494.41%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(201.55%) | (73.52%) | (25.32%) | (440.83%) | (74.20%) | (42.19%) | 2,245.30% | (230.95%) | (159.39%) | (506.06%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
4,332.07% | 8,101.85% | 1,881.77% | (19,549.34%) | 3,193.06% | 1,094.60% | 0.00% | 0.00% | 0.00% | 416.30% |
Selling, General and Administrative Expense of Revenue |
1,451.62% | 3,515.23% | 1,321.71% | (6,459.91%) | 1,215.62% | 651.45% | 0.00% | 0.00% | 0.00% | 503.58% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
314.97% | 887.86% | 205.08% | (1,469.60%) | 313.89% | 211.67% | 0.00% | 0.00% | 0.00% | 248.54% |
Graham Net Nets |
1.56 | 0.88 | 1.07 | 0.34 | 0.25 | 0.48 | — | — | — | 0.02 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Earnings Yield |
(321.05%) | (66.40%) | (38.33%) | (238.82%) | (19.37%) | (18.33%) | — | — | — | (81.20%) |
Free Cash Flow Yield |
(306.82%) | (54.78%) | (24.77%) | (199.30%) | (18.52%) | (6.74%) | — | — | — | (50.87%) |
Revenue per Share |
0.03 | 0.02 | 0.06 | (0.03) | 0.17 | 0.38 | 0.00 | 0.00 | 0.00 | 4.98 |
Operating CF per Share |
(1.74) | (1.36) | (1.33) | (7.14) | (6.86) | (4.21) | (10.79) | (15.27) | (19.59) | (28.96) |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.03) | (0.03) | (0.10) | 0.00 | (0.18) | 0.00 | (0.95) |
Free Cash Flow per Share |
(1.75) | (1.37) | (1.34) | (7.17) | (6.89) | (4.31) | (10.79) | (15.46) | (19.59) | (29.91) |
Cash per Share |
1.19 | 2.61 | 6.16 | 2.39 | 10.32 | 35.95 | 0.93 | 13.77 | 22.44 | 11.65 |
Shareholders Equity per Share |
0.93 | 2.28 | 5.90 | 1.74 | 9.81 | 32.07 | (3.92) | 7.44 | 14.95 | 2.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.93 | 2.28 | 5.90 | 1.74 | 9.81 | 32.07 | (3.92) | 7.44 | 14.95 | 2.46 |
Free Cash Flow |
(66.59) | (42.29) | (25.87) | (49.93) | (45.46) | (12.35) | (15.76) | (14.70) | (9.06) | (7.50) |
Working Capital |
34.15 | 69.46 | 115.55 | 12.93 | 65.23 | 99.93 | (1.19) | 10.83 | 9.56 | 2.01 |
Capital Expenditures |
(0.15) | (0.19) | (0.06) | (0.21) | (0.20) | (0.28) | — | (0.17) | 0.00 | (0.24) |
Net Current Asset Value |
33.90 | 68.13 | 111.31 | 8.50 | 61.07 | 87.81 | (9.92) | 6.69 | 6.66 | 0.28 |
EV/EBIT |
0.21 | 0.00 | 0.19 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Capex to Sales |
0.12 | 0.39 | 0.06 | (0.93) | 0.18 | 0.25 | — | 0.00 | 0.00 | 0.19 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.81) | (0.50) | 0.29 | 0.26 | 0.37 | 0.32 | 0.56 | 0.67 | 0.39 | 0.48 |
Cash ROIC |
(82.28%) | (28.03%) | (11.08%) | (173.86%) | (34.22%) | (6.33%) | 360.46% | (72.85%) | (52.36%) | (211.36%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | (0.74) | 5.86 | 6.40 | — | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.31 | 0.19 | 0.17 | — | 0.20 | — | — |
Average Payables |
1.09 | 1.10 | 2.01 | 2.62 | 1.80 | 1.34 | 1.45 | 1.13 | 1.03 | 0.90 |
Average Assets |
66.45 | 104.00 | 72.37 | 47.87 | 91.46 | 57.03 | 9.89 | 12.65 | 7.50 | 2.35 |
Average Common Equity |
52.96 | 92.34 | 63.18 | 38.40 | 78.34 | 43.12 | 0.67 | 6.99 | 3.76 | (1.19) |
Columns are period end dates